XCUR: Target konsensus Exicure, Inc.

Exicure, Inc. (XCUR) focuses on developing RNA-based therapeutics in collaboration with biopharma partners to combat immune and skin pathologies. The delivery of small oligonucleotide batches is managed via priority air freight, eliminating supply chain disruptions. The current metric stands at 10.33. Historical price action underscores the company's strong position, underpinned by its ownership of patents for safe genetic delivery methods into cells.

The stability of Exicure, Inc. (XCUR) currently depends on the successful acquisition of new assets and a strategic pivot following the cessation of its DNA therapy program. This consensus target chart reflects the average expected share price from experts, linking current capitalization to future potential, which allows investors to identify whether the asset is overvalued or undervalued by comparing current forecasts with historical market phases.